Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant + Palonosetron for CINV in AML/MDS
NCT02205164Phase 2Unknown
- Sponsor
- Associazione Angela Serra (Salento)
- Start
- Oct 2011
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Associazione Angela Serra (Salento). Status: unknown.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02205164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205164.